AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34089698 — intervention group
Group type: COMPARATOR
Intervention: Post-Management of Myelomeningocele Study cohort
Number of subjects: 300
Study 35385330 — intervention group
Group type: EXPERIMENTAL
Intervention: K-Vie™
Number of subjects: 80
Study 35385330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 34078426 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic vacuum therapy (EVT)
Number of subjects: 40
Study 34078426 — intervention group
Group type: COMPARATOR
Intervention: Self‐expanding metal stents (SEMS)
Number of subjects: 40
Study 35482987 — intervention group
Group type: EXPERIMENTAL
Intervention: Reishimmune-S 500 mg/day orally for 14 days
Number of subjects: 0
Study 33031652 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 4716
Study 33031652 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4716
Study 35305280 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Number of subjects: 44
Study 35305280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 32757387 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate temporization
Number of subjects: 49
Study 32757387 — intervention group
Group type: COMPARATOR
Intervention: Delayed temporization
Number of subjects: 49
Study 34408823 — intervention group
Group type: EXPERIMENTAL
Intervention: BIT-mCI group (80 h of BIT followed by 20 h of mCIMT)
Number of subjects: 20
Study 34408823 — intervention group
Group type: EXPERIMENTAL
Intervention: mCIMT-B group (80 h of mCIMT followed by 20 h of BIT)
Number of subjects: 20
Study 34408823 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 20
Study 32090766 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week internet-based self-help program
Number of subjects: 418
Study 32090766 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 418
Study 34826137 — intervention group
Group type: EXPERIMENTAL
Intervention: Copenhagen Original Long Cut at pH 5.0
Number of subjects: 40
Study 34826137 — intervention group
Group type: EXPERIMENTAL
Intervention: Copenhagen Original Long Cut at pH 7.7
Number of subjects: 40
Study 34826137 — intervention group
Group type: EXPERIMENTAL
Intervention: Copenhagen Original Long Cut at pH 8.2
Number of subjects: 40
Study 34826137 — intervention group
Group type: EXPERIMENTAL
Intervention: Copenhagen Original Long Cut at pH 8.6
Number of subjects: 40
Study 32534809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks
Number of subjects: 7
Study 36356657 — intervention group
Group type: EXPERIMENTAL
Intervention: Efzofitimod 1 mg/kg
Number of subjects: 37
Study 36356657 — intervention group
Group type: EXPERIMENTAL
Intervention: Efzofitimod 3 mg/kg
Number of subjects: 37
Study 36356657 — intervention group
Group type: EXPERIMENTAL
Intervention: Efzofitimod 5 mg/kg
Number of subjects: 37
Study 36356657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 36356657 — intervention group
Group type: EXPERIMENTAL
Intervention: Efzofitimod 3 mg/kg and 5 mg/kg
Number of subjects: 37
Study 34411627 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 µg fentanyl with 10 mg hyperbaric bupivacaine
Number of subjects: 124
Study 34411627 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µg fentanyl with 10 mg hyperbaric bupivacaine
Number of subjects: 124
Study 34411627 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 µg fentanyl with 10 mg hyperbaric bupivacaine
Number of subjects: 124
Study 34411627 — intervention group
Group type: COMPARATOR
Intervention: 0 µg fentanyl with 10 mg hyperbaric bupivacaine (Control Group IV)
Number of subjects: 124
Study 32324238 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose azithromycin (20 mg/kg/d)
Number of subjects: 48
Study 32324238 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose azithromycin (10 mg/kg/d)
Number of subjects: 48
Study 32324238 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 48
Study 35511454 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO) + RT + TMZ (patients without baseline corticosteroids)
Number of subjects: 716
Study 35511454 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) + RT + TMZ (patients without baseline corticosteroids)
Number of subjects: 716
Study 32370931 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive group (n = 44)
Number of subjects: 91
Study 32370931 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 47)
Number of subjects: 91
Study 33719473 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person smoking cessation intervention
Number of subjects: 81
Study 33719473 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based smoking cessation intervention
Number of subjects: 81
Study 33719473 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 81
Study 32553471 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-based contrast during HSG
Number of subjects: 1119
Study 32553471 — intervention group
Group type: COMPARATOR
Intervention: Water-based contrast during HSG
Number of subjects: 1119
Study 34637770 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunger condition (fasting for 14 hours)
Number of subjects: 108
Study 34637770 — intervention group
Group type: COMPARATOR
Intervention: Satiated condition (eating breakfast before the study)
Number of subjects: 108
Study 32174296 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy adapted for health anxiety (CBT-HA)
Number of subjects: 444
Study 32174296 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 444
Study 33443030 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated cascade testing strategy (engagement strategies with a patient navigator, an educational video, and accessible genetic testing services)
Number of subjects: 450
Study 33443030 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (proband‐mediated information sharing, sharing a family letter)
Number of subjects: 450
Study 32479320 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training for left dorsolateral prefrontal cortex (DLPFC) activity
Number of subjects: 6
Study 36178294 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-driven patient empowerment intervention (NEI)
Number of subjects: 178
Study 36178294 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 178
Study 34607194 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Opioid Drug Counseling (ODC) plus buprenorphine
Number of subjects: 357
Study 34607194 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine alone
Number of subjects: 357
Study 32869248 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional depression prevention training (IG)
Number of subjects: 394
Study 32869248 — intervention group
Group type: COMPARATOR
Intervention: Pain competence training (CG)
Number of subjects: 394
Study 34329669 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpleasant odor context
Number of subjects: 69
Study 34329669 — intervention group
Group type: COMPARATOR
Intervention: Pleasant odor context
Number of subjects: 69
Study 34329669 — intervention group
Group type: COMPARATOR
Intervention: No odor context
Number of subjects: 69
Study 32350735 — intervention group
Group type: COMPARATOR
Intervention: Microporous polypropylene mesh (SP‐PPL)
Number of subjects: 52
Study 32350735 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene mesh (LP‐PTFE)
Number of subjects: 52
Study 36335278 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 99
Study 33350604 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactiplantibacillus plantarum 299 and 299v (Lp299 and Lp299v)
Number of subjects: 0
Study 33350604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34730810 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-Clonidine-Dexamethasone (BCD) admixed with Bupivacaine (BPV)
Number of subjects: 98
Study 34730810 — intervention group
Group type: COMPARATOR
Intervention: Plain Bupivacaine (BPV)
Number of subjects: 98
Study 33587286 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 53
Study 33587286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 36228577 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatment (MT)
Number of subjects: 105
Study 36228577 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 105
Study 36228577 — intervention group
Group type: COMPARATOR
Intervention: Combination of multimodal treatment with aerobic training (CT)
Number of subjects: 105
Study 32479641 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 198
Study 32479641 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 198
Study 32479641 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab
Number of subjects: 198
Study 32532299 — intervention group
Group type: EXPERIMENTAL
Intervention: Females with borderline high and above total cholesterol (TC ≥ 200 mg/dL)
Number of subjects: 26378
Study 32532299 — intervention group
Group type: EXPERIMENTAL
Intervention: Females with borderline high and above triglycerides (TG ≥ 150 mg/dL)
Number of subjects: 26378
Study 32532299 — intervention group
Group type: EXPERIMENTAL
Intervention: Females with borderline high and above low-density lipoprotein cholesterol (LDL-C ≥ 130 mg/dL)
Number of subjects: 26378
Study 32532299 — intervention group
Group type: EXPERIMENTAL
Intervention: Females with low high-density lipoprotein cholesterol (HDL-C < 40 mg/dL)
Number of subjects: 26378
Study 32532299 — intervention group
Group type: COMPARATOR
Intervention: Males with borderline high and above TC, TG, and LDL-C
Number of subjects: 26378
Study 32532299 — intervention group
Group type: EXPERIMENTAL
Intervention: Females with borderline high and above TC, TG, and LDL-C
Number of subjects: 26378
Study 32532299 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for dyslipidemia in males
Number of subjects: 26378
Study 32532299 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for dyslipidemia in females
Number of subjects: 26378
Study 35581749 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening testing (17:00–19:00) for knee extensors
Number of subjects: 27
Study 35581749 — intervention group
Group type: COMPARATOR
Intervention: Morning testing (07:00–09:00) for knee extensors
Number of subjects: 27
Study 35581749 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening testing (17:00–19:00) for elbow flexors
Number of subjects: 27
Study 35581749 — intervention group
Group type: COMPARATOR
Intervention: Morning testing (07:00–09:00) for elbow flexors
Number of subjects: 27
Study 35581749 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening testing (17:00–19:00) for biceps brachii
Number of subjects: 27
Study 35581749 — intervention group
Group type: COMPARATOR
Intervention: Morning testing (07:00–09:00) for vastus lateralis
Number of subjects: 27
Study 35581749 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening testing (17:00–19:00) for knee extension in males
Number of subjects: 27
Study 35581749 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening testing (17:00–19:00) for knee extension in females
Number of subjects: 27
Study 34815354 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab alone (arm A)
Number of subjects: 60
Study 34815354 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab combined with cetuximab (arm B)
Number of subjects: 60
Study 33400656 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular learning framework for classification with weak supervision using implicit pairwise labels.
Number of subjects: 10
Study 33400656 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular training approach
Number of subjects: 10
Study 33400656 — intervention group
Group type: EXPERIMENTAL
Intervention: Method for estimating reusability of pretrained modules
Number of subjects: 10
Study 33594443 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Gait Training (VRT)
Number of subjects: 55
Study 33594443 — intervention group
Group type: COMPARATOR
Intervention: Non-Virtual Reality Gait Training (non-VRT)
Number of subjects: 55
Study 32634815 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Cut-Off (MCO) dialyzers
Number of subjects: 52
Study 32634815 — intervention group
Group type: COMPARATOR
Intervention: High-Flux dialyzers
Number of subjects: 52
Study 35491518 — intervention group
Group type: EXPERIMENTAL
Intervention: GIPR antagonist GIP(3‐30)NH2 (1,200 pmol/kg/min) with GLP‐1 infusion (0.75 pmol/kg/min)
Number of subjects: 10
Study 35491518 — intervention group
Group type: EXPERIMENTAL
Intervention: GIPR antagonist GIP(3‐30)NH2 with GLP‐1 infusion
Number of subjects: 10
Study 35491518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 33601214 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen vegetable-based meals
Number of subjects: 51
Study 33601214 — intervention group
Group type: COMPARATOR
Intervention: Commercial sterilized meals in jars
Number of subjects: 51
Study 35706870 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium 400 μg tablets, taken three times a week after each hemodialysis session for 3 months
Number of subjects: 78
Study 35706870 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 78
Study 33408365 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-locus negative frequency-dependent selection (NFDS) combined with asymmetrical recombination favoring deletion of accessory loci over insertion.
Number of subjects: 0
Study 33408365 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-locus negative frequency-dependent selection (NFDS)
Number of subjects: 0
Study 33408365 — intervention group
Group type: COMPARATOR
Intervention: Symmetrical recombination
Number of subjects: 0
Study 33408365 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetrical recombination
Number of subjects: 0
Study 34011404 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective ventilation group with tidal volume (VT) of 7 ml/kg of predicted body weight (PBW) and optimal PEEP
Number of subjects: 64
Study 34011404 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective ventilation group
Number of subjects: 64
Study 34011404 — intervention group
Group type: COMPARATOR
Intervention: Traditional ventilation group with tidal volume (VT) of 9 ml/kg of predicted body weight (PBW)
Number of subjects: 64
Study 32179237 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye movements intervention during recall of aversive memory
Number of subjects: 68
Study 32179237 — intervention group
Group type: COMPARATOR
Intervention: Control condition (recall without eye movements)
Number of subjects: 68
Study 36017005 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 32
Study 36017005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 33881796 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin
Number of subjects: 360
Study 33881796 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 360
Study 32315648 — intervention group
Group type: EXPERIMENTAL
Intervention: Floor Sitting-Rising Test (SRT)
Number of subjects: 240
Study 34686780 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 376
Study 34686780 — intervention group
Group type: EXPERIMENTAL
Intervention: selective internal radiation therapy
Number of subjects: 376
Study 34686780 — intervention group
Group type: COMPARATOR
Intervention: baseline imaging features
Number of subjects: 376
Study 33571839 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic morcellation with the TruClearTM 8.0 Tissue Removal System
Number of subjects: 83
Study 33571839 — intervention group
Group type: COMPARATOR
Intervention: Bipolar resection with a rigid 8.5‐mm resectoscope
Number of subjects: 83
Study 33571839 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic morcellation
Number of subjects: 83
Study 33130569 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosexual education about medical and behavioural treatment options for sexual dysfunction delivered by a haematology nurse consultant; emotionally focused therapy-based relationship education programme for couples delivered by a clinical psychologist (four sessions of 1.5 hours each).
Number of subjects: 15
Study 33130569 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosexual intervention for couples post-transplantation.
Number of subjects: 15
Study 34165763 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-bearing (WB) exercise
Number of subjects: 15
Study 34165763 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-weight-bearing (NON-WB) exercise
Number of subjects: 15
Study 34489366 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth-facilitated personalized intervention
Number of subjects: 21
Study 34826995 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation training
Number of subjects: 40
Study 34826995 — intervention group
Group type: COMPARATOR
Intervention: Routine care (without meditation)
Number of subjects: 40
Study 33688068 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised, trauma-informed yoga
Number of subjects: 21
Study 33688068 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise
Number of subjects: 21
Study 33767247 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Medicine
Number of subjects: 177
Study 32050105 — intervention group
Group type: EXPERIMENTAL
Intervention: Photochemotherapy (PCT) with toluidine blue photosensitizer and 660 nm diode laser
Number of subjects: 50
Study 32050105 — intervention group
Group type: COMPARATOR
Intervention: Local antibiotic therapy (LAT) with metronidazole gel
Number of subjects: 50
Study 34455545 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Number of subjects: 78
Study 34455545 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 78
Study 34455545 — intervention group
Group type: COMPARATOR
Intervention: Stretching-toning control group
Number of subjects: 78
Study 33573612 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum avoidance practice
Number of subjects: 398
Study 33573612 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for discarding colostrum
Number of subjects: 398
Study 33573612 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with less likelihood of discarding colostrum
Number of subjects: 398
Study 32886267 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Semaglutide
Number of subjects: 0
Study 35598005 — intervention group
Group type: EXPERIMENTAL
Intervention: 40mg of methylprednisolone once a day for 5 days
Number of subjects: 0
Study 35598005 — intervention group
Group type: EXPERIMENTAL
Intervention: 80mg of methylprednisolone once a day for 5 days
Number of subjects: 0
Study 35598005 — intervention group
Group type: EXPERIMENTAL
Intervention: 120mg of methylprednisolone once a day for 5 days
Number of subjects: 0
Study 35598005 — intervention group
Group type: COMPARATOR
Intervention: Standard ICU patient care + 100ml of normal saline once a day for 5 days (Control group)
Number of subjects: 0
Study 33493153 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention directed towards staff members focusing on palliative care
Number of subjects: 203
Study 33493153 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 203
Study 32788083 — intervention group
Group type: EXPERIMENTAL
Intervention: G-MEDSS (Computerised Clinical Decision Support System)
Number of subjects: 26
Study 32788083 — intervention group
Group type: EXPERIMENTAL
Intervention: G-MEDSS
Number of subjects: 26
Study 36085067 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Goal Attainment Program (PGAP) intervention consisting of a maximum of 10 weekly individual sessions provided by a trained PGAP professional.
Number of subjects: 0
Study 36085067 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (care as usual).
Number of subjects: 0
Study 33982187 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity (HI) resistance training [75% of one‐repetition maximum (1RM), 4 sets, 10 reps]
Number of subjects: 30
Study 33982187 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Blood-Flow Restricted (LIBFR) exercise [20% of 1RM, 4 sets, 30 + 15 + 15 + 15 reps]
Number of subjects: 30
Study 33982187 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study 33048656 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive online educational intervention utilizing avatars depicting distressed individuals
Number of subjects: 85
Study 33048656 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 85
Study 33048656 — intervention group
Group type: COMPARATOR
Intervention: Post-test only group (not specified)
Number of subjects: 85
Study 33386831 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoelectrically controlled FES (MeCFES) followed by robotic therapy (MRG)
Number of subjects: 18
Study 33386831 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation care (CG)
Number of subjects: 18
Study 33325251 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Number of subjects: 0
Study 33325251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33542427 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual dose-volume histograms (IDVHs) method for PTV DVH prediction
Number of subjects: 150
Study 33542427 — intervention group
Group type: COMPARATOR
Intervention: Distance-to-target histogram and conformal-plan-dose-volume histogram (DTH + CPDVH) method for OAR DVH prediction
Number of subjects: 150
Study 33693464 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (50 mg daily for 90-120 days)
Number of subjects: 21
Study 33693464 — intervention group
Group type: COMPARATOR
Intervention: Preintervention period (no iron supplementation)
Number of subjects: 21
Study 33693464 — intervention group
Group type: EXPERIMENTAL
Intervention: Postintervention period (after iron supplementation)
Number of subjects: 21
Study 32657029 — intervention group
Group type: EXPERIMENTAL
Intervention: SP regimen (raltitrexed plus cisplatin)
Number of subjects: 135